Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications

por De Placido, S, De Angelis, C, Giuliano, M, Pizzi, C, Ruocco, R, Perrone, V, Bruzzese, D, Tommasielli, G, De Laurentiis, M, Cammarota, S, Arpino, G, Arpino, G
Publicado en Br J Cancer (2017)

Role of vesicular nucleotide transporter VNUT (SLC17A9) in release of ATP from AR42J cells and mouse pancreatic acinar cells

por Haanes, K. A., Kowal, J. M., Arpino, G., Lange, S. C., Moriyama, Y., Pedersen, P. A., Novak, I.
Publicado 2014

Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up

por Malorni, L., Shetty, P. B., De Angelis, C., Hilsenbeck, S., Rimawi, M. F., Elledge, R., Osborne, C. K., De Placido, S., Arpino, G.
Publicado 2012

Tumor characteristics and prognosis in familial breast cancer

por Arpino, G., Pensabene, M., Condello, C., Ruocco, R., Cerillo, I., Lauria, R., Forestieri, V., Giuliano, M., De Angelis, C., Montella, M., Crispo, A., De Placido, S.
Publicado en BMC Cancer (2016)

Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a...

por De Angelis, C., Bruzzese, D., Bernardo, A., Baldini, E., Leo, L., Fabi, A., Gamucci, T., De Placido, P., Poggio, F., Russo, S., Forestieri, V., Lauria, R., De Santo, I., Michelotti, A., Del Mastro, L., De Laurentiis, M., Giuliano, M., De Placido, S., Arpino, G.
Publicado en ESMO Open (2021)

Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel an...

por De Angelis, C., Bruzzese, D., Bernardo, A., Baldini, E., Leo, L., Fabi, A., Gamucci, T., De Placido, P., Poggio, F., Russo, S., Forestieri, V., Lauria, R., De Santo, I., Caputo, R., Cianniello, D., Michelotti, A., Del Mastro, L., De Laurentiis, M., Giuliano, M., De Placido, S., Arpino, G.
Publicado en ESMO Open (2021)

Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer:...

por Malorni, L, Curigliano, G, Minisini, A M, Cinieri, S, Tondini, C A, D’Hollander, K, Arpino, G, Bernardo, A, Martignetti, A, Criscitiello, C, Puglisi, F, Pestrin, M, Sanna, G, Moretti, E, Risi, E, Biagioni, C, McCartney, A, Boni, L, Buyse, M, Migliaccio, I, Biganzoli, L, Di Leo, A
Publicado en Ann Oncol (2018)

T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study

por Schettini, F., Conte, B., Buono, G., De Placido, P., Parola, S., Griguolo, G., Fabi, A., Bighin, C., Riccardi, F., Cianniello, D., De Laurentiis, M., Puglisi, F., Pelizzari, G., Bonotto, M., Russo, S., Frassoldati, A., Pazzola, A., Montemurro, F., Lambertini, M., Guarneri, V., Cognetti, F., Locci, M., Generali, D., Conte, P., De Placido, S., Giuliano, M., Arpino, G., Del Mastro, L.
Publicado en ESMO Open (2021)